Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Lenvatinib As Up-front Therapy for Unresectable HCCПодробнее

Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCCПодробнее

Implication of Upfront Lenvatinib in HCCПодробнее

Dr. Finn on Role of Lenvatinib in HCC Treatment ParadigmПодробнее

Lenvatinib plus pembro for aRCC - update on the CLEAR studyПодробнее

Phase III Findings for Lenvatinib in HCCПодробнее

Treatment for Advanced-stage HCCПодробнее

First-Line Therapy in Advanced HCCПодробнее

Molecular Targeted Therapies for Advanced HCCПодробнее

Lenvatinib and Everolimus for Advanced RCCПодробнее

Dr. Bastholt on Lenvatinib in Thyroid CancerПодробнее

Treatment Approach to Metastatic Hepatocellular CarcinomaПодробнее

LEAP-002: Lenvatinib Plus Pembrolizumab for First-Line Advanced HCC?Подробнее

Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCCПодробнее

Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumabПодробнее

IMbrave150 Trial: Combination Therapy in Advanced HCCПодробнее

Lenvatinib for Hepatocellular CarcinomaПодробнее

Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCCПодробнее

Frontline Lenvatinib vs Sorafenib in HCCПодробнее